A retrospective cohort study of patients presenting with cardiotoxicity after treatment with fluoropyrimidines suggests that switching to S-1 (i.e. a combination of tegafur, gimeracil, and oteracil, at a molar ratio of 1:0.4:1) is safe for these patients and supports treatment continuation .
Prof. Pia Österlund (Tampere University Hospital, Finland) presented a multicentre retrospective cohort study, including patients with solid tumours who experienced fluoropyrimidine-related cardiotoxicity and were re-challenged with a different fluoropyrimidine or S-1 and then assessed for cardiotoxicity.
Cardiotoxicity during capecitabine (n=124), continuous (n=13), or bolus 5-fluorouracil (n=4) was reported for 141 patients prior to switching to S-1 therapy. Cardiotoxicity was defined as chest pain including vasospasm without cardiac findings (55%), acute coronary syndrome or myocardial infarctio...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« REGOMUNE: a phase 2 study combining regorafenib and avelumab Next Article
Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.